Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pleural Effusion II: Symptoms and Management

Pleural Effusion II: Symptoms and Management

Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...

Pneumothorax-II

Pneumothorax-II

Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:

Pleural Effusion I: Introduction

Pleural Effusion I: Introduction

Pleural effusion is an abnormal fluid accumulation in the pleural cavity, a narrow space between the lungs and the chest wall. It is not a disease per se but rather a symptom or indication of an underlying disease. In normal circumstances, this space contains a small amount of fluid (5 to 15 mL), a lubricant facilitating the non-frictional movement of the pleural surfaces.
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's criteria,...

Acute Respiratory Failure-V

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...

Pleural Disorders: Types and Brief Description

Pleural Disorders: Types and Brief Description

The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Role of consolidative thoracic and prophylactic cranial radiation in extensive stage small cell lung cancer in chemo-immunotherapy era.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2024

Same author

Management of isolated anomalous systemic arterial supply to normal lung (ISSNL) during pregnancy.

QJM : monthly journal of the Association of Physicians·2024

Same author

Generation of the iPSC line FINi002-A from a male Parkinson's disease patient carrying compound heterozygous mutations in the PRKN gene.

Stem cell research·2023

Same author

[Implementation of biosecurity measures by hoof trimmers in Switzerland].

Schweizer Archiv fur Tierheilkunde·2023

Same author

Disseminated BCGosis following Systemic Absorption of Mycobacterium Bovis.

Irish medical journal·2022

Same author

A two-ward acute care hospital outbreak of SARS-CoV-2 delta variant including a point-source outbreak associated with the use of a mobile vital signs cart and sub-optimal doffing of personal protective equipment.

The Journal of hospital infection·2022

Search research articles

Related Experiment Video

Updated: Jun 2, 2026

Local Anesthetic Thoracoscopy for Undiagnosed Pleural Effusion

Local Anesthetic Thoracoscopy for Undiagnosed Pleural Effusion

Published on: November 10, 2023

Optimal therapy of malignant pleural effusions.

T Lynch¹, L Kalish, S Mentzer

¹BRIGHAM & WOMENS HOSP,DIV THORAC SURG,BOSTON,MA 02115. BRIGHAM & WOMENS HOSP,DIV HEMATOL ONCOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CLIN ONCOL,BOSTON,MA 02115. HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV BIOSTAT,BOSTON,MA 02115.

International Journal of Oncology

|May 6, 2011

Summary

This study compared bleomycin, tetracycline, and talc for malignant pleural effusion (MPE). While no significant differences were found in the trial, a meta-analysis suggests bleomycin may be superior for MPE management.

More Related Videos

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

Related Experiment Videos

Last Updated: Jun 2, 2026

Local Anesthetic Thoracoscopy for Undiagnosed Pleural Effusion

Local Anesthetic Thoracoscopy for Undiagnosed Pleural Effusion

Published on: November 10, 2023

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

Area of Science:

Pulmonology
Oncology
Clinical Trials

Background:

Malignant pleural effusion (MPE) is a common complication of cancer, causing significant morbidity.
Sclerotherapy is a standard palliative treatment for MPE, aiming to obliterate the pleural space.
The optimal sclerosing agent for MPE remains a subject of investigation.

Purpose of the Study:

To compare the efficacy and safety of bleomycin, tetracycline, and talc as sclerosing agents for MPE.
To determine the optimal approach for managing malignant pleural effusion.
To conduct a meta-analysis of existing trials comparing bleomycin and tetracycline.

Main Methods:

A randomized phase III trial involving 50 patients with MPE.
Patients were randomized to receive bleomycin, tetracycline, or talc after chest tube drainage.
A meta-analysis of four previous trials comparing bleomycin and tetracycline was also performed.

Main Results:

The trial was prematurely terminated due to the withdrawal of parenteral tetracycline.
No significant differences were observed between bleomycin, tetracycline, and talc in 30-day effusion control, survival, resclerosis rates, pain, fever, or hospitalization duration.
The meta-analysis revealed a 20.6% advantage for bleomycin over tetracycline (p=0.002).

Conclusions:

This phase III trial lacked sufficient power to detect clinically significant differences between the three sclerosing agents.
Meta-analysis data suggest bleomycin may be a superior sclerosing agent for malignant pleural effusion.
The findings highlight the need for novel approaches to palliate malignant pleural effusion.